Company News
Talley Medical’s Negative Pressure Wound Therapy products are now available on Drug Tariff
Talley Group are pleased to confirm that the Venturi™ Canisters and Venturi™ Wound Sealing Kits have been included within Drug Tariff Part 1X.
The products will be listed in the September 2008 edition of the Drug Tariff within the Dressings, Wound Management Dressings, Topical Negative Pressure System Accessories section.
Continue Reading | Posted: Friday, August 15th, 2008
Talley Group receive FDA clearance to market Venturi™ system in the United States
Talley Group are delighted to announce that the Venturi™ Negative Pressure Wound Therapy system has received clearance from the FDA.
Talley Group CEO Chris Evans stated
With over 2 years of European experience in the NPWT arena, the FDA’s clearance to market the product in the US clearly demonstrates the International attention the Venturi™ product range has attracted. We are looking forward to working with our partners to develop the exciting business opportunities
Continue Reading | Posted: Wednesday, July 16th, 2008
Venturi™ Negative Pressure Wound Therapy products awarded onto NHS Supply Chain Contract
Talley Group Ltd today announced that their Venturi™ Negative Pressure Wound Therapy products including the pump system, dressing kits and canisters have been included on the new NHS Supply Chain Advanced Woundcare and Topical Negative Pressure Therapy Contract. CM/MCD/07/4921
The NHS Supply Chain procurement process used independent product councils made up from clinical experts who evaluated the evidence supporting each product. Products awarded onto the contract also had to meet new standards of clinical and cost effectiveness that promote best practice in wound care.
Continue Reading | Posted: Monday, June 23rd, 2008
Talley Group Ltd exhibit at World Union of Wound Healing Societies conference
Talley Group Ltd exhibited Venturi™, their cost effective, clinically proven Negative Pressure Wound Therapy (NPWT) product.
Venturi™ has already achieved remarkable growth since its launch in the UK and Europe and Talley were delighted with the international interest shown in the product when it was showcased at the World Union of Wound Healing Societies event in Toronto Canada.
Continue Reading | Posted: Tuesday, June 10th, 2008
Talley Medical’s pressure area care products are now available to order through NHS Supply Chain
Talley Group Ltd today announced that their pressure area care products have been included on the new Pressure area care framework agreement - CM/MSS/05/3740.
Customers are now able to purchase Talley Medical’s range of clinically proven dynamic pressure relieving products, through the NHS Supply Chain route.
Continue Reading | Posted: Tuesday, May 27th, 2008
Talley Group Ltd relieving the pressure in Italy
Sanitaria Scaligera, Talley’s exclusive mattress distributor in Italy have purchased a significant volume of Quattro™ Plus and Quattro™ Overlay, specialist pressure relieving mattresses from the Talley Medical Quattro™ range that will be used in recently awarded contracts in the Emilia Romagna region of Italy.
Featuring up to 32 independent air-cells and powered by a sophisticated pump system, these mattress products inflate and deflate in a cycle ensuring the skin is put under no direct pressure, preventing pressure sores developing, and healing existing problems.
Continue Reading | Posted: Monday, April 28th, 2008
Talley Group Ltd announce new partnership
The Talley Group Ltd and Andersen Caledonia Ltd announce their new partnership in the development and promotion of TECare™ products and services.
Andersen Caledonia, one of the UK’s leading independent suppliers of microbiological testing and sterilization services to the healthcare industry, is to develop a range of clinical solutions using the TECare™ antimicrobial products that will provide hospitals with a new weapon to fight nosocomial infections in critical areas.
Continue Reading | Posted: Friday, April 11th, 2008
Talley announce the latest independent TECare™ laboratory test results
Hospital Infection Research Laboratory, Birmingham, UK have conducted EN1276 quantitative suspension efficacy testing on TECare™ antimicrobial fluid using four organisms; Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae.
Continue Reading | Posted: Friday, March 28th, 2008